MJBizDaily’s recent piece argues that the cannabis industry must give genetics a strategic role beyond marketing. For breeders, seedbanks and commercial growers that means clear provenance, investment in breeding and data, and active stewardship to protect diversity, IP and supply resilience. This editorial explains what the argument means in practical terms for professionals and where the industry will need attention next.

The Psychiatric Times argues that cannabis policy affects psychiatric outcomes in ways that go beyond simple legality. This editorial unpacks the policy levers at work, who in the sector should take notice and what practical steps regulators, clinicians and industry actors can reasonably expect or demand next.

MJBizDaily has highlighted a simple proposition: genetics are the cannabis industry’s most valuable asset. For breeders, seedbanks, producers and distributors that claim to sell consistency, potency or therapeutic value, that statement should change how contracts, quality assurance and corporate strategy are organised.

Wholesale buyers looking for feminized cannabis seeds need more than a familiar strain name. Prioritise genetic provenance, phenotype stability, germination performance, batch traceability, IP and licensing, and consistent B2B terms. This article provides practical checks and commercial implications to help seedbanks, distributors and growshops evaluate suppliers and align selections to catalogue strategy.

This article explains why provenance is a commercial procurement issue for seedbanks, breeders and distributors. It gives practical checks to assess genetic origin, traceability and supplier fit so you can reduce catalogue risk, protect IP and plan reliable product lines.

A concise framework for seedbanks, growshops, breeders and distributors to evaluate cannabis genetics suppliers beyond price: catalogue fit, provenance, consistency, IP and licensing, logistics, commercial terms and quality assurance. Practical checks and decision criteria that help procurement teams reduce risk and secure a supply partner aligned with their product and market strategy.

DNA Genetics published a Top 5 list for 2025 via Ganjapreneur. This article explains what that announcement means commercially for seedbanks, breeders, growshops, distributors and professional genetics buyers, and sets out concrete procurement and catalogue checks to act on.

This article answers the question "feminized vs autoflower vs F1" from the standpoint of a professional buyer. It summarises technical differences, explains commercial consequences for sourcing and catalogue structure, and gives a clear supplier-evaluation checklist you can use when choosing genetics partners.